About: Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia
Creator	Toth, S Toth, Stefan Dominik, Pella Fedacko, Fedacko, J Pella, D Ther, Cardiol
Source	PMC
abstract	Despite progress in both primary and secondary prevention, cardiovascular diseases (CVD) are still the largest group of ailments contributing to morbidity and mortality worldwide. Atherosclerotic changes, the primary pathological substrate for CVD, are closely related to hypercholesterolemia. Therefore, the treatment of hypercholesterolemia is a key therapeutic strategy for CVD management. Statins, as the gold standard in the treatment of hypercholesterolemia, have shown enhanced cardiac outcomes in many randomized clinical trials. However, often despite the maximum allowed and tolerated dosage of statins, we are not able to reach the target cholesterol levels, and thus patients persist at an increased cardiovascular risk. Recently, most of the large clinical studies in the field of preventive cardiology have focused on proprotein convertase subtilisin kexin type 9 (PCSK9) and its activity regulation. PCSK9 plays an essential role in the metabolism of LDL particles by inhibiting LDL receptor recirculation to the cell surface. Recent studies have shown that inhibition of PCSK9 by the administration of monoclonal antibodies is capable of significantly reducing LDL levels (up to an additional 60%) as well as reducing the incidence of CVD. However, this treatment procedure of administering the anti-PCSK9 antibodies, most frequently two times a month, has its limitations in terms of time, patient adherence, and nevertheless cost. Administration of active vaccination instead of passive immunization with anti-PCSK9 antibodies may be an effective way of controlling blood cholesterol levels. However, clinical data, as well as human testing, are still inadequate. This work aims to provide an overview of PCSK9 vaccines and their potential clinical benefit.
has issue date	2020-07-31(xsd:dateTime)
bibo:doi	10.1007/s40119-020-00191-6
bibo:pmid	32737796
has license	cc-by-nc
sha1sum (hex)	907e77e1146c756fb5cb5eaee878602a667ea9e0
schema:url	https://doi.org/10.1007/s40119-020-00191-6
resource representing a document's title	Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia
has PubMed Central identifier	PMC7394273
has PubMed identifier	32737796
schema:publication	Cardiol Ther
resource representing a document's body	covid:907e77e1146c756fb5cb5eaee878602a667ea9e0#body_text
is schema:about of	named entity 'gold standard' named entity 'Targeting' named entity 'PROGRESS' named entity 'SECONDARY PREVENTION' named entity 'THERAPEUTIC' named entity 'Despite' named entity 'mortality' named entity 'therapeutic' named entity 'Statins' named entity 'hypercholesterolemia' named entity 'secondary prevention' named entity 'hypercholesterolemia' named entity 'substrate' named entity 'cardiovascular diseases' named entity 'Vaccines' named entity 'immunization' named entity 'measles' named entity 'humoral' named entity 'conjugated' named entity 'inclisiran' named entity 'vaccine' named entity 'total cholesterol' named entity 'dyslipidemias' named entity 'plasma cells' named entity 'peptide' named entity 'LDL-C' named entity 'KLH' named entity 'epitope' named entity 'CD8' named entity 'CD4 cells' named entity 'antibodies' named entity 'gene mutations' named entity 'PCSK9' named entity 'adaptive immune response' named entity 'Total cholesterol' named entity 'CD8' named entity 'T-helper cells' named entity 'T-helper cells' named entity 'antigen' named entity 'LDL-C' named entity 'T-cell' named entity 'LDL' named entity 'vaccination' named entity 'passive immunization' named entity 'antibodies' named entity 'preclinical studies' named entity 'antibodies' named entity 'lymphocyte' named entity 'PCSK9' named entity 'lysosomal degradation' named entity 'squalene' named entity 'hypertension' named entity 'alirocumab' named entity 'adaptive immune response' named entity 'vaccine' named entity 'antigens' named entity 'Antigen' named entity 'pathogen' named entity 'LDL-C' named entity 'epitope' named entity 'atherosclerosis' named entity 'lymphocytes' named entity 'APC' named entity 'ApoB' named entity 'CD4 cells' named entity 'short half-life' named entity 'antigens' named entity 'Open Access' named entity 'review article' named entity 'clinical study' named entity 'CD4' named entity 'immune response' named entity 'PCSK9' named entity 'CpG oligonucleotide' named entity 'LDL-C'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software